Bausch Health Companies Inc. announced that its dental products subsidiary, OraPharma, will extend its commercial presence into Canada and Puerto Rico, marking a significant expansion of the company’s dental portfolio into two new geographic markets.
The expansion will be phased, with no specific launch dates disclosed. Bausch Health said it will strengthen relationships with local distributors in both countries, although the partners have not yet been named. The company’s goal is to broaden access to its flagship periodontal treatment, Arestin, the only FDA‑approved locally applied antibiotic used with scaling and root planing.
Canada and Puerto Rico present large unmet needs for periodontal care. In Canada, 70 % of adults suffer from periodontal disease, while in Puerto Rico 44.5 % of older adults are affected. Arestin’s proven efficacy positions OraPharma to capture a meaningful share of these markets and address a high‑volume, high‑revenue opportunity.
Bausch Health’s broader strategy is to diversify beyond its core gastroenterology and hepatology businesses. The company’s Q3 2025 results—revenue of $2.68 billion, up 7 % YoY, and adjusted EBITDA of $986 million, up 8 %—supported a raised full‑year revenue guidance of $5.0 billion to $5.1 billion. The dental expansion aligns with this growth trajectory and adds a new revenue stream that can help sustain the company’s momentum.
Tom Stern, Vice President and General Manager of OraPharma, said the move “will help address gaps in care and provide dental professionals with a proven treatment option for adult periodontitis patients.” His comments underscore the company’s focus on meeting unmet medical needs while expanding its market reach.
The expansion is a material milestone that strengthens Bausch Health’s diversification strategy, adds a high‑potential revenue source, and demonstrates the company’s commitment to improving oral health outcomes in underserved markets. By leveraging Arestin’s established track record and the growing prevalence of periodontal disease, Bausch Health positions itself to capture a significant share of the Canadian and Puerto Rican dental markets while supporting its broader growth objectives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.